Minimed GroupMMED +0.14%15 EBIT per Share is $-0.47 as of Jan. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, Minimed Group ranks worse than 144927.39% on this metric.
Minimed Group's EBIT per Share for the
three
months ended in Jan. 2026 was $-0.33.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.47.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Minimed Group's EBIT per Share or its related term are showing as below:
MMED's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.65 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Minimed Group's EBIT for the
three
months ended in Jan. 2026 was $-93 Mil.
Minimed Group (NAS:MMED) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Minimed Group EBIT per Share Related Terms
Minimed Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Minimed Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (MMED) has a EBIT per Share of $-0.47 as of Jan. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Minimed Group and its competitors. According to the industry distribution chart, Minimed Group ranks #999999 out of 690 companies in the Medical Devices & Instruments industry.
Is Minimed Group's EBIT per Share too high?
Minimed Group's current EBIT per Share is $-0.47. Based on the distribution chart, Minimed Group ranks #999999 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's EBIT per Share compare to ICUI and WRBY?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #999999 out of 690 companies for EBIT per Share. This places Minimed Group in the lower half of its industry. The industry median EBIT per Share is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current EBIT per Share is $-0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current EBIT per Share of $-0.47. The current EBIT per Share is $-0.47. Minimed Group's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Minimed Group (MMED), the current EBIT per Share is $-0.47 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score
Get the complete analysis for MMED
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMED has been successfully added to your 